Spontaneous tumour regression is a well-recognised phenomenon in infantile favourable-biology neuroblastoma. An ‘expectant-observation’ strategy avoids chemotherapy or surgery associated risks but has mostly been limited to small tumours (diameter < 5 cm) and discontinued if significant tumour growth or increasing catecholamine levels. Here we report the successful use of an observation-only strategy in an infant with unresectable neuroblastoma > 5 cm at diagnosis which initially tripled in size with a 10-fold increase in urinary catecholamines. We highlight the need for consensus evidence-based criteria to define the subgroup where a ‘wait-and-see’ approach is appropriate and criteria to begin active treatment.
No takes yet. Share an insight, caveat, or question.
Hinchliffe et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: